Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and Older

NCT04840992 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT04840992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04840992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and Older
Lead sponsor
CanSino Biologics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 21, 2021
Completion date
August 9, 2022
Enrollment
840 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19